Indivior PharmaceuticalsINDV +3.80%75 Net Margin % is 28.08% as of Mar. 2026, which is 552% above its 10-year median of 4.31. GuruFocus rates INDV with a GF Score™ of 75/100 and a GF Value™ of $22.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Indivior Pharmaceuticals ranks better than 86.4% on this metric.
The historical rank and industry rank for Indivior Pharmaceuticals's Net Margin % or its related term are showing as below:
INDV'
s Net Margin % Range Over the Past 10 Years
Min: -22.87 Med: 4.31 Max: 27.36
Current: 19.44
INDV's Net Margin % is ranked better than 86.4% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs INDV: 19.44
Indivior Pharmaceuticals (NAS:INDV) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Indivior Pharmaceuticals Net Margin % Related Terms
Indivior Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indivior Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Indivior Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indivior Pharmaceuticals (INDV) has a Net Margin % of 28.08% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Indivior Pharmaceuticals and its competitors. This is 552% above median its historical median of 4.31. According to the industry distribution chart, Indivior Pharmaceuticals ranks #130 out of 956 companies in the Drug Manufacturers industry, placing it in the top 13.6%.
Is Indivior Pharmaceuticals' Net Margin % too high?
Indivior Pharmaceuticals' current Net Margin % of 28.08% is 552% above median its 10-year median of 4.31. The Drug Manufacturers industry median Net Margin % is 5.56. Indivior Pharmaceuticals' value of 28.08% is 405% above this industry median. Based on the distribution chart, Indivior Pharmaceuticals ranks #130 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Indivior Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Net Margin % compare to AMRX and KNSA?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #130 out of 956 companies for Net Margin %. This places Indivior Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Indivior Pharmaceuticals' value of 28.08% is 405% above this benchmark. While the company's 10-year median is 4.31 vs. the industry median of 5.56, Indivior Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indivior Pharmaceuticals's current Net Margin % of 28.08% is 405% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Indivior Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indivior Pharmaceuticals's current Net Margin % is 28.08%, which is 552% above median its own 10-year median of 4.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.99, compared to a current price of $41.48 — trading 80.4% above its estimated fair value. The current Net Margin % is 28.08%, which is 552% above median its 10-year median of 4.31 and 405% above the Drug Manufacturers industry median of 5.56. Indivior Pharmaceuticals' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Net Margin % is 28.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?
Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued.
The current stock price of $41.48 is trading 80.4% above its estimated GF Value™ of $22.99.
GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INDV:
Net Margin %: 28.08% (552% above median its 10-year median of 4.31)
GF Value™: $22.99 vs. price of $41.48 (80.4% above fair value)
Industry Position: 405% above the Drug Manufacturers median (#130 of 956)
No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
75GF Score
Get the complete analysis for INDV
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDV has been successfully added to your 
